AtriCure, Inc. (ATRC) Stock: Price, Forecast & Analyst Target
AtriCure, Inc. (ATRC) — MoonshotScore 95/100 (Exceptional band), calculated Nov 18, 2026. Price $55.45 (+0.78%), as of the Nov 18, 2026 trading session; market cap $2.82B.
Educational signal · not a buy or sell recommendation · How to read this
AtriCure, Inc. · ATRC · NASDAQ
AtriCure, Inc. is a medical device company specializing in surgical ablation solutions for cardiac tissue and intercostal nerves. Their devices are used in medical centers across the United States, Europe, Asia, and internationally.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · AtriCure (ATRC)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, a fortress balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 3 of the last 4 reports
- Altman Z 9.71 · Piotroski F 8
- ROE 2.9% · ROA 1.6% · current ratio 4.33
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 96 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $55.45 | |
| Change on the day | +0.78% | |
| 52-week range | $25.36 – $66.02 | |
| Market capitalisation | $2.82B | — |
| Price / earnings (trailing) | 182.85 | |
| Shares traded on the day | 595.2K |
Price & events
Other perspectives
Council score for AtriCure (ATRC): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is AtriCure (ATRC), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. AtriCure, Inc. (ATRC) is listed on NASDAQ. It employs 1,350 people and is led by Michael H. Carrel. The market values it at $2.82B.
What do the latest results show for AtriCure (ATRC)?
Short answer · as of
Against analyst estimates the company has EPS beat 3 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $134M | -$267,000 | -$0.01 (diluted) |
| Q4 FY2025 | $141M | $2M | $0.04 (diluted) |
| Q1 FY2026 | $141M | $108,000 | $0.0022 (diluted) |
| Q2 FY2026 | $154M | $9M | $0.18 (diluted) |
What are the financial strengths and risks for AtriCure (ATRC)?
Short answer
The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 9.71 · Piotroski F 8. Trailing ratios: ROE 2.9% · ROA 1.6% · current ratio 4.33.
What should you watch next at AtriCure (ATRC)?
Short answer · as of
Current published price targets run low $50.00 · high $70.00 · consensus $62.00 · median $64.00 against a quoted price of $55.45 (as of Nov 18, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does AtriCure compare with its peers?
Short answer
AtriCure's score ranks 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| AtriCure (ATRC) — this page | $55.45 | $2.82B | 95 |
| $75.58 Nov 18, 2026 | $1.73B | 88 5-pillar Nov 18, 2026 | |
| $272.70 Nov 18, 2026 | $656B | 83 5-pillar Nov 18, 2026 | |
| $122.86 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $85.93 Nov 18, 2026 | $5.15B | 81 5-pillar Nov 18, 2026 | |
| $25.35 Nov 18, 2026 | $1.27B | 80 5-pillar Nov 18, 2026 | |
| $43.64 Nov 18, 2026 | $63.3B | 77 5-pillar Nov 18, 2026 | |
| $15.36 Nov 18, 2026 | $4.20B | 73 5-pillar Nov 18, 2026 | |
| $178.48 Nov 18, 2026 | $4.46B | 73 5-pillar Nov 18, 2026 | |
| $104.49 Nov 18, 2026 | $181B | 69 5-pillar Nov 18, 2026 | |
| $48.69 Nov 18, 2026 | $2.03B | 64 5-pillar Nov 18, 2026 | |
| $28.22 Nov 18, 2026 | $3.51B | 62 5-pillar Nov 18, 2026 | |
| $8.52 Nov 18, 2026 | $1.70B | 31 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $50.00 – $70.00
- Consensus target
- $62.00
- Median target
- $64.00
Consensus record · Captured .
Measured against a quoted price of $55.45 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026
- Transactions
- 21
- Identified insiders
- 11
- Purchases
- 0
- Sales
- 12
- Other transactions
- 9
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ATRC in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ATRC in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about AtriCure (ATRC)?
- AtriCure (ATRC) Stock Looks Fully Priced Even After Its 66% Run
- AtriCure to Participate in the Piper Sandler 38th Annual Healthcare Conference
- AtriCure Management Discusses Strategic Growth and Financial Outlook at UBS Global Healthcare Conference
- AtriCure, Inc. (ATRC) Presents at 2026 UBS Global Healthcare Conference Transcript
Investor Questions: ATRC Stock
These answers are editorial: 1 of these 9 answers is drawn from the ATRC research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ATRC?
ATRC carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. AtriCure, Inc. is a medical device company specializing in surgical ablation solutions for cardiac tissue and intercostal nerves.
Is ATRC a good stock to buy?
Stock Expert AI does not rate ATRC buy, sell or hold. AtriCure, Inc. carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ATRC stock price today?
The last price recorded for AtriCure, Inc. (ATRC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ATRC price target?
The analyst consensus price target for AtriCure, Inc. (ATRC), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for ATRC?
The main risks for AtriCure, Inc. include intense competition from larger medical device companies, which could impact market share and pricing. Product liability claims and recalls are inherent risks in the medical device industry.
What are the key factors to evaluate for ATRC?
AtriCure, Inc. (ATRC) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. The company's focus on surgical ablation of cardiac tissue addresses a significant and growing market need, particularly in the treatment of atrial fibrillation. Not financial advice.
How frequently does ATRC data refresh on this page?
ATRC's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ATRC's recent stock price performance?
AtriCure, Inc. (ATRC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product portfolio in cardiac ablation. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ATRC overvalued or undervalued right now?
The trailing P/E of AtriCure, Inc. (ATRC) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 11 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com